Renal Cancer
|
New Targets in Development
|
Prognostic test to estimate recurrence risk following surgery: Development stage
|
|
U.S. Incidence of Renal Cancer
|
40,000/Year1
|
About Renal Cancer Treatment and Genomic Health's Products in Development
Renal, or kidney, cancer is diagnosed when cancerous growths are found in a person´s
kidneys. In adults, the most common type of renal cancer is known as renal cell
carcinoma. Renal cancer is often detected when people are undergoing procedures
for other diseases. The incidence of renal cancer seems to be increasing although
the reason is not well understood. People who smoke are at increased risk for renal
cell carcinoma, and
genetics may also play a factor. Drugs shown to be effective in
late-stage renal cancer have not yet been established for benefit in early-stage
disease.
Genomic Health is collaborating with Pfizer Inc. to identify prognostic genes that
could lead to development of a test to estimate the risk of recurrence following
surgery that may aid in the subsequent identification of early stage patients with
renal cell carcinoma who could benefit most from treatment. A study involving over
900 patients looking at more than 700 candidate genes is currently underway
For more information about renal cancer, visit the National Cancer Institute´s
Kidney Cancer
page or the nonprofit group Kidney Cancer Association´s website at
www.kidneycancer.org.
Learn more about additional Genomic Health products in development:
- Mattson Jack, CancerMPact August 2009 (2010 incidence).
